May 4, 2022

Poxel Announces Availability of Its 2021 Universal Registration Document

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that the Universal Registration Document (Document d'Enregistrement Universel) for the year ended December 31, 2021 has been filed with the French market authority (Autorité des Marchés Financiers, or AMF).

This document is available in English on the AMF's website and on Poxel's website www.poxelpharma.com in the Investors / Shareholder Information / Regulatory Documentation section (in English and in French).

The 2021 Universal Registration Document includes:

- the 2021 Annual Financial Report, including the Management Report; and
- the Report on Corporate Governance

This year, the Company's URD includes a new version of the Corporate Social Responsibility (CSR) Report. This document reflects the review and evaluation of Poxel existing CSR actions performed in 2021, and describes its CSR strategy. The report will be available on the Company's website, in the Investors / Corporate-governance section.

Printed copies of the universal registration document are also available to the public free of charge and upon request at the Company's headquarters located Immeuble Le Sunway, 259-261 Avenue Jean Jaurès, 69007 Lyon, France.

About Poxel SA

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **non-alcoholic steatohepatitis (NASH)** and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, **PXL065** (deuterium-stabilized *R*-pioglitazone) is in a streamlined Phase 2 trial (DESTINY-1). **PXL770**, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). **TWYMEEG®** (Imeglimin), Poxel's first-in-class lead product

that targets mitochondrial dysfunction, has been approved and launched for the treatment of type 2 diabetes in Japan. Poxel expects to receive royalties and sales-based payments from Sumitomo Pharma. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com.

View source version on businesswire.com:
https://www.businesswire.com/news/home/20220504006115/en/

Investor relations / Media
Aurélie Bozza
Investor Relations & Communication Senior Director
aurelie.bozza@poxelpharma.com
+33 6 99 81 08 36

Elizabeth Woo
Senior Vice President, Investor Relations & Communication
elizabeth.woo@poxelpharma.com

NewCap
Emmanuel Huynh or Arthur Rouillé
poxel@newcap.eu
+33 1 44 71 94 94

Source: POXEL SA